1. Le DT, Uram JN, Wang H et al. PD-1 blockade in tumors with mismatchrepair deficiency.
N Engl J Med 2015; 372 (26): 2509–2520. 2. Gerlinger M, Rowan AJ, Horswell S et al …

Variants of uncertain significance in precision oncology: nuance or nuisance? Page 1 The
Oncologist, 2024, XX, 1–4 https://doi.org/10.1093/oncolo/oyae135 Advance access publication …

The molecular characterization of patient tumors provides a rational and highly promising
approach for guiding oncologists in treatment decision-making. Notwithstanding, genomic …

In 2012, the University of Texas MD Anderson Cancer Center in Houston partnered with IBM
to develop the artificial intelligence program, called IBM Watson, as a clinical decision tool in …

The concept of precision oncology involves the prescription of therapies that target the
molecular driver alterations of an individual patient's tumor. This treatment paradigm has …

Randomized clinical trials often set the standard of care for the treatment of early-stage
breast cancer. However, the low event rates in these studies often require large sample …

The rapid development of artificial intelligence (AI) technologies in the context of the vast
amount of collectable data obtained from high-throughput sequencing has led to an …

With the increasing availability of genomics, routine analysis of advanced cancers is now
feasible. Treatment selection is frequently guided by the molecular characteristics of a …

ORIGINAL ARTICLE Charoentong, P. et al. Pan-cancer immunogenomic analyses reveal
genotypeimmunophenotype relationships and predictors of response to checkpoint …

(1) Background: Precision oncology has the potential to improve patient health and
wellbeing through targeted prevention and treatment. Owing to uncertain clinical and …